These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12161147)

  • 1. Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
    Cheng Y; Zhang F; Rano TA; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Rutkowski CA; Lin JH; Jin L; Emini EA; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2419-22. PubMed ID: 12161147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
    Duffy JL; Kevin NJ; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2423-6. PubMed ID: 12161148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
    Cheng Y; Rano TA; Huening TT; Zhang F; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Lin JH; Xu X; Jin L; Olah TV; McLoughlin DA; King RC; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Feb; 12(4):529-32. PubMed ID: 11844665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
    Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.
    Raghavan S; Yang Z; Mosley RT; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Emini EA; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2855-8. PubMed ID: 12270162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
    Kevin NJ; Duffy JL; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4027-30. PubMed ID: 14592500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
    Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
    Duffy JL; Rano TA; Kevin NJ; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2569-72. PubMed ID: 12852968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
    Zhang F; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2573-6. PubMed ID: 12852969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys.
    Jin L; Chen IW; Chiba M; Lin JH
    Xenobiotica; 2003 Jun; 33(6):643-54. PubMed ID: 12851040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
    Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
    Chen X; Weber IT; Harrison RW
    J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
    Raghavan S; Lu Z; Beeson T; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Gabryelski L; Emini E; Tata JR
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5432-6. PubMed ID: 17692518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.
    Armbruster C; Vorbach H; Steindl F; El Menyawi I
    J Antimicrob Chemother; 2001 Apr; 47(4):487-90. PubMed ID: 11266428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.